Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | PRKCA | P17252 | 5/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | DGKA | P23743 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14963998 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2AHPGDHTTGAA | |
| SCHEMBL16983769 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2AHPGDHTTGAA | |
| SCHEMBL37833 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2AHPGDHTTGAA | |
| SCHEMBL6046844 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2AHPGDHTTGAA | |
| SCHEMBL905722 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2AHPGDHTTGAA | |
| SCHEMBL379163 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2AHPGDHTTGAA | |
| SCHEMBL1870550 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2AHPGDHTTGAA | |
| SCHEMBL905404 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2AHPGDHTTGAA | |
| SCHEMBL4960230 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2AHPGDHTTGAA | |
| SCHEMBL6046845 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2AHPGDHTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3922260-A2 | INSULIN RECEPTOR PARTIAL AGONISTS AND GLP-1 ANALOGUES | MERCK SHARP & DOHME CORP. (US) | 2021-12-15 | — | — | EP | disclosed |
| US-11058775-B2 | Insulin dimer-incretin conjugates | MERCK SHARP & DOHME CORP. (US) | 2021-07-13 | — | — | US | disclosed |
| US-10953076-B2 | Insulin receptor partial agonists and GLP-1 analogues | MERCK SHARP & DOHME CORP. (US) | 2021-03-23 | — | — | US | disclosed |
| US-10800827-B2 | Insulin receptor partial agonists | MERCK SHARP & DOHME CORP. (US) | 2020-10-13 | — | — | US | disclosed |
| EP-3221343-B1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME (US) | 2020-09-16 | — | — | EP | disclosed |
| US-20190192675-A1 | INSULIN DIMER-INCRETIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190142906-A1 | INSULIN RECEPTOR PARTIAL AGONISTS AND GLP-1 ANALOGUES | MERCK SHARP & DOHME CORP. (US) | 2019-05-16 | — | — | US | disclosed |
| US-20190092833-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2019-03-28 | — | — | US | disclosed |
| US-10183981-B2 | Insulin receptor partial agonists | MERCK SHARP & DOHME LLC | 2019-01-22 | — | — | US | disclosed |
| US-10017556-B2 | Insulin receptor partial agonists | MERCK SHARP & DOHME CORP. (US) | 2018-07-10 | — | — | US | disclosed |
| EP-2287184-A2 | Novel insulin derivatives | NOVO NORDISK A/S (DK) | 2011-02-23 | — | — | EP | disclosed |
| EP-2275439-A2 | Novel insulin derivatives | NOVO NORDISK A/S (DK) | 2011-01-19 | — | — | EP | disclosed |
| EP-2264065-A2 | Novel Insulin Derivatives | NOVO NORDISK A/S (DK) | 2010-12-22 | — | — | EP | disclosed |
| EP-2264066-A2 | Novel insulin derivatives | NOVO NORDISK A/S (DK) | 2010-12-22 | — | — | EP | disclosed |
| US-20100009899-A1 | Novel Insulin Derivatives | NOVO NORDISK A/S (DK) | 2010-01-14 | — | — | US | disclosed |
| US-7615532-B2 | Antidiabetic agents; insulin derivatives which are naturally occurring insulins or analogues thereof which have a side chain attached either to the alpha-amino group of the N-terminal amino acid residue of the B chain or to epsilon-amino group of a Lys residue present in the B chain of parent insulin | NOVO NORDISK A/S (DE) | 2009-11-10 | — | — | US | disclosed |
| EP-2107069-A2 | Novel insulin derivatives | NOVO NORDISK A/S (DK) | 2009-10-07 | — | — | EP | disclosed |
| US-20060183668-A1 | Antidiabetic agents; insulin derivatives which are naturally occurring insulins or analogues thereof which have a side chain attached either to the alpha-amino group of the N-terminal amino acid residue of the B chain or to epsilon-amino group of a Lys residue present in the B chain of parent insulin | NOVO NORDISK A/S (DK) | 2006-08-17 | — | — | US | disclosed |
| EP-1660531-A2 | NOVEL INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005012347-A2 | NOVEL INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800827-B2 | Insulin receptor partial agonists | INSR, GPR119, IRS1 | SMN1; SMN2 3416/4885KMT2A 4174/4885HPGD 3295/4885 |
| US-20190192675-A1 | INSULIN DIMER-INCRETIN CONJUGATES | IAPP, GLP1R, GIPR | SMN1; SMN2 1610/4885KMT2A 4623/4885HPGD 2981/4885 |
| US-20190092833-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | SMN1; SMN2 3416/4885KMT2A 4174/4885HPGD 3295/4885 |
| US-11058775-B2 | Insulin dimer-incretin conjugates | IAPP, GLP1R, GIPR | SMN1; SMN2 1610/4885KMT2A 4623/4885HPGD 2981/4885 |
| US-20190142906-A1 | INSULIN RECEPTOR PARTIAL AGONISTS AND GLP-1 ANALOGUES | GLP1R, GIPR, IAPP | SMN1; SMN2 2538/4885KMT2A 2161/4885HPGD 3263/4885 |
| US-10953076-B2 | Insulin receptor partial agonists and GLP-1 analogues | GLP1R, GIPR, IAPP | SMN1; SMN2 2538/4885KMT2A 2161/4885HPGD 3263/4885 |
| US-10183981-B2 | Insulin receptor partial agonists | INSR, GPR119, IRS1 | SMN1; SMN2 3416/4885KMT2A 4174/4885HPGD 3295/4885 |
| US-10017556-B2 | Insulin receptor partial agonists | INSR, GPR119, IRS1 | SMN1; SMN2 3416/4885KMT2A 4174/4885HPGD 3295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.